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Abstract. Breast cancer is one of the most commonly diag-
nosed cancers in women around the world. In general, the 
more aggressive the tumor, the more rapidly it grows and the 
more likely it metastasizes. Members of the Rho subfamily 
of small GTP-binding proteins (GTPases) play a central role 
in breast cancer cell motility and metastasis. The switch 
between active GTP-bound and inactive GDP-bound state 
is regulated by guanine nucleotide exchange factors (GEFs), 
GTPase-activating proteins (GAPs) and guanine-nucleotide 
dissociation inhibitors (GDIs). We studied the role of StarD13, 
a recently identified Rho-GAP that specifically inhibits the 
function of RhoA and Cdc42. We aimed to investigate its 
role in breast cancer proliferation and metastasis. The levels 
of expression of this Rho-GAP in tumor tissues of different 
grades were assayed using immunohistochemistry. We 
observed that, while the level of StarD13 expression decreases 
in cancer tissues compared to normal tissues, it increases as 
the grade of the tumor increased. This was consistent with the 
fact that although StarD13 was indeed a tumor suppressor in 
our breast cancer cells, as seen by its effect on cell prolifera-
tion, it was needed for cancer cell motility. In fact, StarD13 
knockdown resulted in an inhibition of cell motility and cells 
were not able to detach their tail and move forward. Our study 
describes, for the first time, a tumor suppressor that plays a 
positive role in cancer motility.
Introduction
Breast cancer is one of the most commonly diagnosed cancers 
in women around the world. Ductal and lobular carcinomas 
are the two most frequent types of breast cancer. They can be 
either non-invasive, referred to as in situ carcinoma, or inva-
sive infiltrating carcinoma (1). According to the US National 
Cancer Institute, breast cancer can be classified into five 
progressive stages. Stage 0 is referred to as carcinoma in situ, 
which can be either ductal carcinoma in situ (DCIS) or lobular 
carcinoma in situ (LCIS). DCIS may become invasive in later 
stages of the tumor and spread to other tissues (2,3). Invasive 
breast carcinoma can be classified into progressive stages Ι-ΙV 
depending on its size and its presence or absence at secondary 
sites, mainly the lymph nodes.
Cell motility is a complex multistep process that integrates 
multiple intracellular signaling and regulatory pathways. 
Therefore, slight modifications in any step may dramatically 
affect normal cellular functions and result in cellular trans-
formation and carcinogenesis. It is known that cell motility is 
essential for metastasis and without it tumors would be easily 
eradicated and/or surgically removed (1). The acquisition of 
a motile phenotype is a critical step towards carcinogenesis 
and is required for a cell to gain metastatic competence. Thus, 
further descriptions of the molecular mechanisms regulating 
cancer cell motility would facilitate the development of 
specific and effective therapeutic treatments against metastasis 
and tumor cell invasion (1,4).
Members of the Rho-family GTPases are small GTP- 
binding proteins (GTPases) that range between 20-40 kDa in 
size. Almost all aspects of tumor cell proliferation, motility and 
invasion including cellular polarity, cytoskeletal re-organiza-
tion, and signal transduction pathways are controlled through 
the interplay between the Rho-GTPases (5,6). Frequent studies 
have shown that the Rho family GTPases regulate cell motility 
in breast cancer through their ability to mediate the remod-
eling of the actin cytoskeleton as well as translating cellular 
signals from the plasma membrane receptors to regulate focal 
adhesion, cell polarity, vesicular trafficking and gene expres-
sion (6). Approximately 30% of human tumors possess a 
specific mutation in Ras oncogene leading to its protein level 
overexpression or constitutive activation. In contrast to Ras, 
no mutation in any of the Rho GTPases has been identified in 
breast cancer. Rather, these GTPases are often either overex-
pressed or hyperactive in breast cancer tissue. The variations 
in the levels of these Rho proteins might directly correlate 
with the advancement of breast cancer (7,8). The three most 
characterized members of the Rho GTPases are Rho, Rac and 
Cdc42 which were found to be distinct in function from the 
other Rho proteins (9). Rho GTPases are negatively regulated 
by Rho GTPases activating proteins (GAPs). These proteins 
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inhibit Rho GTPases by activating their intrinsic GTPase 
activity. This leads to the hydrolysis of the bound GTP into 
GDP converting Rho GTPases back to their inactive confor-
mation (10). In addition to activating GTP hydrolysis, GAPs 
may function as effectors of Rho GTPases to mediate other 
downstream effector functions (6,11)
DLC2 gene was first identified by Ching et al (12). It is 
located on position 13q12.3 and was found to be underex-
pressed in hepatocellular carcinoma (12). DLC2 is commonly 
known as steriodogenic acute regulatory protein-related lipid 
transfer domain-containing protein 13 (StarD13). StarD13 
shares 64% homology with DLC1, another member of the 
DLC family (13). StarD13 has an N-terminal SAM motif and a 
C-terminal START domain. It also harbors a RhoGAP domain, 
which is important to its function (12-14). Overexpression of 
StarD13 was found to associate with significant decrease in 
cell growth and proliferation in hepatocellular carcinoma (12). 
Moreover, DLC1, a closely related protein is found to be under-
expressed in many types of cancer including lung, prostate, 
kidney, colon, breast, uterus and stomach (15). Also, previous 
data in astrocytoma suggest a potential role of StarD13 as a 
tumor suppressor (16).
In this study we aimed at characterizing StarD13 in breast 
cancer in terms of its level of expression and its role in cellular 
proliferation, motility and invasion. The level of expression 
of StarD13 was determined in patient tissues representing 
different grades of breast cancer compared to normal tissues. 
The effect on cellular proliferation, viability and cell cycle 
progression upon manipulating the level of StarD13 expres-
sion was then studied in addition to investigating its RhoGAP 
activity in cancer cell motility as well as its effect on cellular 
invasion in vitro.
Materials and methods
Cell culture. Human breast cancer cell lines (MCF-7 and 
MDA-MB-231) obtained from ATCC, were cultured in 
DMEM medium supplemented with 10% FBS and 100 U 
penicillin/streptomycin at 37˚C and 5% CO2 in a humidified 
chamber.
Antibodies and reagents. Goat polyclonal anti-StarD13 anti-
body was obtained from Santa Cruz Biotechnology. Mouse 
monoclonal anti-RhoA, mouse monoclonal anti-Rac1, and 
mouse monoclonal anti-paxillin antibodies were purchased 
from Upstate Biotechnology (Lake Placid, NY, USA). Anti-
goat and anti-mouse HRP-conjugated secondary antibodies 
were obtained from Promega. Fluorescent secondary anti-
bodies (AlexaFluor 488) were obtained from Invitrogen. 
To visualize the actin cytoskeleton, cells were stained with 
Rhodamine phalloidin (Invitrogen). DAPI was also used to 
stain nuclei.
Cell transfection with siRNA. Goat FlexiTube siRNA for 
StarD13, RhoA, and Rac1 were obtained from Qiagen. The 
siRNAs used had the following target sequences: StarD13: 
5'-CCCGCAATACGCTCAGTTATA-3', RhoA: 5'-TTCGGAA 
TGATGAGCACACAA-3', and Rac1: 5'-ATGCATTTCCTG 
GAGAATATA-3'. The cells were transfected with the siRNA 
at a final concentration of 10 nM using HiPerfect (Qiagen) as 
described by the manufacturer. Control cells were transfected 
with siRNA sequences targeting GL2 Luciferase (Qiagen). 
After 72 h, protein levels in total cell lysates were analyzed by 
western blotting using the appropriate antibodies or the effect 
of the corresponding knockdown was assayed.
Cell transfection with vectors. Cells were transfected with 
5 µg GFP-StarD13, dominant active RhoA, or control empty 
control vectors using Lipfectamine LTX with Plus reagent 
(Invitrogen) as described by the manufacturer. Cells were 
incubated with the transfection complexes for 4 h then refed 
with DMEM supplied with 30% FBS. The experiments were 
carried on 24 h following transfection. The GFP-StarD13 and 
the RhoA constructs were generous gifts from respectively 
Dr Hitoshi Yagisawa from the University of Hyogo, Japan and 
Dr Hideki Yamaguchi from the Albert Einstein College of 
Medicine, NY, USA.
The constructs were transformed into One Shot TOP10 
chemically competent E. coli (Invitrogen), which were grown 
on a selective medium containing the appropriate antibiotic. 
The vectors were then extracted using MaxiPrep plasmid 
extraction kit from Qiagen. The mCherry-tagged RhoA-DA 
construct was a generous gift from Dr Louis Hodgson from 
Albert Einstein College of Medicine Yeshiva University, NY, 
USA.
Western blotting. Cell lysates were prepared by scraping 
the cells in a sample buffer consisted of 4% SDS, 10% 
β-mercaptoethanol, 20% glycerol, 0.004% bromophenol 
blue, and 0.125 M Tris-HCl at a pH 6.8. The resulting lysates 
were boiled for 5 min. Protein samples were separated by 
SDS-PAGE on 8% (for StarD13) or 15% (for RhoA and Rac) 
gels and transferred to PVDF membranes overnight at 30 V. 
The membranes were then blocked with 5% non-fat dry milk 
in PBS containing 0.1% Tween-20 for 1 h at room temperature 
and incubated with primary antibody at a concentration of 
1:100 for 2 h at room temperature. After the incubation with the 
primary antibody, the membranes were washed and incubated 
with secondary antibody at a concentration of 1:1,000 for 1 h 
at room temperature. The membranes were then washed, and 
the bands visualized by treating the membranes with western 
blotting chemiluminescent reagent ECL (GE Healthcare). The 
results were obtained on X-ray film (Agfa Healthcare). The 
levels of protein expression were compared by densitometry 
using ImageJ software.
RT-PCR. Cells were grown in 6-well plate at density of 
1x106 cells/ml and were transfected by either control or 
StarD13 siRNA for 72 h. Total RNA was extracted performed 
RNeasy extraction kit (Qiagen) according to the manufacturer's 
instructions. Reverse transcriptase polymerase chain reaction 
(RT-PCR) was used to amplify RNA of StarD13. RNA (2 µg) 
was converted to cDNA using the OneStep RT-PCR kit 
(Qiagen) as described by the manufacturer. Briefly, gene-
specific primers designed to detect cDNA were obtained from 
TIB-MolBiol with the following sequences: forward, 5'-AGC 
CCCTGCCTCAAAGTATT-3'; reverse, 5'-AGCCCCTGCCTC 
AAAGTATT-3'. β-actin was used as a control with primers 
obtained from Sigma-Aldrich having the following sequences: 
forward, 5'-ATGAAGATCCTGACCGAGCGT-3'; reverse, 
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5'-AACGCAGCTCAGTAACAGT-CCG-3'. Primers were used 
at a final concentration of 0.6 µM. Primers were added to 
5X Qiagen OneStep RT-PCR buffer providing a final concen-
tration of 2.5 mM MgCl2 in the reaction mix. A final 
concentration of 400 µM of each dNTP was added along with 
2.0 µl/reaction of enzyme mix. Final mastermix volume was 
adjusted to 50 µl using RNase-free water. Thermal cycler 
conditions, for both reverse transcription and PCR, was 
programmed as follows: reverse transcription at 50˚C for 
30 min, initial PCR activation step at 95˚C for 15 min, followed 
by 25 cycles of denaturation at 94˚C for 1 min, annealing at 
52˚C for 1 min and extension at 72˚C for 1 min followed by a 
final extension step at 72˚C for 10 min. The PCR products 
(10 µl) were run on 0.8% agarose gel stained with ethidium 
bromide at 100 V for 30 min. The resulting bands were visual-
ized under UV light and photographed. β-actin was used as a 
loading control.
Antigen retrieval and immunohistochemistry. Permission for 
tissue collection was granted by the Committee on Human 
Subjects in Research (CHSR) at the Lebanese American 
University (approval given March 26, 2010, CHSR tracking 
no. NSMS26032010-1). Human breast cancer tissues different 
grades were provided by Dr Selim Nasser from Clemenceau 
Medical Center (CMC), Beirut, Lebanon. Tissue blocks were 
paraffin-embedded and sectioned to 8-µm sections using 
a tissue microtome. Sections were deparaffinized in two 
changes of xylene 5 min each then hydrated in two changes of 
95% alcohol 2 min each followed by 2 changes of 50% alcohol 
2 min each. Antigen retrieval was then performed in pre-
heated Citra Plus (Biogenex) solution. Tissues were then fixed 
with 4% paraformaldehyde for 10 min, and permeabilized 
with 0.5% Triton-X100 for 10 min. To decrease background 
fluorescence, tissues were rinsed with 0.1 M glycine then incu-
bated with 0.1 M glycine for 10 min. For blocking, tissues were 
incubated 4 times with 1% BSA, 1% FBS in PBS for 5 min. 
Samples were stained with StarD13 primary antibody for 2 h 
and with a fluorophore-conjugated secondary antibody for 2 h. 
Tissue fluorescent images were taken using a 10X objective 
on a fluorescent microscope. For image analysis, all digital 
images were imported in  ImageJ software (National Institutes 
of Health, MA, USA). The total fluorescence intensity of a 
fixed area from ≥10 different frames from each tissue was 
determined.
Trypan blue exclusion method. Cells were grown in 24-well 
plates (growth area: 2 cm2) at a density of 2x106 cells/ml. 
Depending on the experiment, cells were transfected with 
either StarD13 siRNA or GFP-StarD13 construct. Following 
treatment period, the supernatant from each well was collected, 
cells were washed with PBS, and the PBS washes were added 
to the supernatant of each well. Cells were then trypsinized 
and collected separately from the well contents and PBS. From 
each collection tube 20 µl was mixed with 20 µl of trypan 
blue, 10 µl of this mixture was placed in a counting chamber 
under the microscope, and the number of living and dead cells 
was recorded accordingly. For each well, two countings were 
done separately, PBS washes/well supernatant and trypsinized 
cells. Under the microscope, dead cells appear blue, since they 
are permeable to trypan blue, while viable cells exclude the 
stain and thus appear bright. The percentage of dead cells was 
reported.
Cell proliferation reagent (WST-1). Cells were seeded in 
96-well plates (growth area: 0.6 cm2) at a concentration of 
1x106 cells/ml. Depending on the experiment, cells were trans-
fected with either StarD13 siRNA or GFP-StarD13 construct 
with appropriate controls. Following treatment period, 10 µl 
of cell proliferation reagent (WST-1; Roche, Germany) was 
added to each well. The plates were incubated at in a humidi-
fied incubator (37˚C) in 95% air and 5% CO2 for 2 h. WST-1 
is a tetrazolium salt that on contact with metabolically active 
cells is cleaved to produce formazan dye by mitochondrial 
dehydrogenases. Quantitation of formazan is done colori-
metrically at 450 nm. The absorbance of the each blank well 
was subtracted from the corresponding sample well. The 
results were normalized to the corresponding controls, and the 
percent of cell proliferation was reported.
Pull-down assay. Cells were either transfected with 
GFP-StarD13 construct or an empty GFP construct as a 
control. Following treatment period, cells were lysed and 
the pull-down assay performed using the RhoA/Rac1/Cdc42 
Activation Assay Combo Kit (Cell BioLabs) following the 
manufacturer's instructions. Briefly, cell lysates were incubated 
with GST-RBD (for RhoA) or GST-PAK (for Rac1/Cdc42) 
for 1 h at 4˚C with gentle agitation. Then, the samples were 
centrifuged, and the pellet washed for several times. After the 
last wash, the pellets were resuspended with sample buffer 
and boiled for 5 min. GTP-RhoA and GTP-Rac1/Cdc42 were 
detected by western blotting using anti-RhoA, anti-Rac1 and 
anti-Cdc42 antibodies provided in the kit. Total proteins were 
collected prior to the incubation with GST beads and used as 
a loading control.
Cell cycle analysis. Treated cells were placed into 15 ml 
Falcon tubes and centrifuged at 1,500 rpm for 5 min. The 
pellet was then washed and resuspended in 1 ml of ice-cold 
1X phosphate-buffered saline (PBS) followed by 4 ml of 
70% ethanol. Cells were then left overnight at -20˚C. The 
following day, cells were pelleted and washed with 1X PBS. 
The pellet was resuspended in 500 µl of 1X binding buffer 
and then stained with 10 µl of propidium iodide (PI) for 
10 min in the dark. Cells were analyzed using an Accuri C6 
flow cytometer (Ann Arbor, MI, USA), which indicated the 
distribution of the cells into their respective cell cycle phases 
based on their DNA content determined by the CFlow® soft-
ware. G0/G1 cells were 2n, S-phase cells were >2n but <4n 
while G2/M cells were 4n.
Immunostaining assay. The cells were plated on cover slips, 
and the appropriate treatment was applied. Cells were fixed 
with 4% paraformaldehyde for 10 min, and permeabilized 
with 0.5% Triton-X100 for 10 min. To decrease background 
fluorescence, cells were rinsed with 0.1 M glycine then incu-
bated with 0.1 M glycine for 10 min. For blocking, cells were 
incubated 4 times with 1% BSA, 1% FBS in PBS for 5 min. 
Samples were stained with primary antibodies for 2 h and 
with fluorophore-conjugated secondary antibodies for 2 h. 
Fluorescent images were taken using a 60X objective on a 
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fluorescent microscope. Average adhesion size was obtained 
by thresholding the image on ImageJ software that calculates 
the average area and size.
Wound healing. Cells were grown to confluence on culture 
plates and a wound was made in the monolayer with a sterile 
pipette tip. After wounding, the cells were washed twice with 
PBS to remove debris and new medium was added. Phase-
contrast images of the wounded area were taken at 0 and 16 h 
after wounding. Wound widths were measured at 11 different 
points for each wound, and the average rate of wound closure 
was calculated in µm/h using the ImageJ software in pixels/h 
and then converted to µm/h by multiplying by the the pixel 
size corresponding the objective used in these experiments.
Motility assay. For motility analysis, images of cells moving 
randomly in serum were collected every 60 sec for 2 h 
using a 20X objective. During imaging, the temperature was 
controlled using a Nikon heating stage which was set at 37˚C. 
The medium was buffered using HEPES and overlayed with 
mineral oil. The speed of cell movement was quantified using 
the ROI tracker plugin in the ImageJ software, which was used 
to calculate the total distance travelled by individual cells. The 
speed is then calculated by dividing this distance by the time 
(120 min) and reported in µm/min. The speed of ≥15 cells for 
each condition was calculated. The net distance travelled by 
the cell was calculated by measuring the distance travelled 
between the first and the last frames.
Adhesion assay. 96-well plates were coated with collagen 
using Collagen Solution, Type I from rat tail (Sigma) over-
night at 37˚C then washed with washing buffer (0.1% BSA 
in DMEM). The plates were then blocked with 0.5% BSA in 
DMEM at 37˚C in a CO2 incubator for 1 h. This was followed 
by washing the plates and chilling them on ice. Meanwhile, 
the cells were trypsinized and counted to 4x105 cell/ml. Cells 
(50 µl) were added in each well and incubated at 37˚C in a CO2 
incubator for 30 min. The plates were then shaken and washed 
3 times. Cells were then fixed with 4% paraformaldehyde 
at room temperature for 10 min, washed, and stained with 
crystal violet (5 mg/ml in 2% ethanol) for 10 min. Following 
the staining with crystal violet, the plates were washed exten-
sively with water, and left to dry completely. Crystal violet was 
solubilized by incubating the cells with 2% SDS for 30 min. 
The absorption of the plates was read at 550 µm using a plate 
reader.
Invasion assay. MDA-MB-231 cells were transfected 
with either control or StarD13 siRNAs and invasion assay 
was performed 48 h following treatment period using the 
collagen-based invasion assay (Millipore) according to the 
manufacturer's instructions. Briefly, 24 h prior to assay, cells 
were starved with serum-free medium. Cells were harvested, 
centrifuged and then resuspended in quenching medium 
(without serum). Cells were then brought to a concentration of 
1x106 cells/ml. In the meantime, inserts were prewarmed with 
300 µl of serum-free medium for 30 min at room temperature. 
After rehydration, 250 µl of media was removed from inserts 
and 250 µl of cell suspension was added. Inserts were then 
placed in a 24-well plate, and 500 µl of complete media (with 
10% serum) was added to the lower wells. Plates were incu-
bated for 24 h at 37˚C in a CO2 incubator. Following incubation 
period, inserts were stained for 20 min at room temperature 
with 400 µl of cell stain provided with the kit. Stain was then 
extracted with extraction buffer (also provided). Extracted 
stain (100 µl) was then transferred to a 96-well plate suitable 
for colorimetric measurement using a plate reader. Optical 
density was then measured at 560 µm.
Statistical analysis. All the results reported represent average 
values from three independent experiments. The error esti-
mates are given as ± SEM. The p-values were calculated by 
t-tests or chi-square tests depending on the experiment using 
the VassarStats: Website for Statistical Computation (http://
vassarstats.net/).
Results
Level of expression of StarD13 in breast cancer. Before 
studying the role of StarD13 in breast cancer cells, we first 
wanted to investigate its level of expression in human breast 
cancer tissues. For this, breast cancer tissue sections were 
obtained from patients representing different grades. We 
performed immunohistochemistry using an anti-StarD13 
antibody (Fig. 1A). The mean fluorescent intensity was then 
measured using the ImageJ software. StarD13 showed a high 
expression level in non-invasive in situ carcinoma. Then, its 
level of expression decreased in grades I and II; however, as 
we moved on to higher grades of the tumor, StarD13 showed a 
significant increase in its level of expression (Fig. 1B).
In order to supplement our results, we mined the oncomine 
database for microarray analysis where they measured StarD13 
mRNA expression levels from 60 breast cancer samples 
grouped by grade. The results showed that StarD13 is under-
expressed in tumor tissues relative to non-tumor (grade 0). 
Moreover, StarD13 mRNA levels are relatively higher when 
compared to levels in lower grade tumors 1 and 2 (Fig. 1C). 
This was consistent with our IHC results.
StarD13 effect on cell viability and proliferation. The 
surprising increase in StarD13 expression level in higher 
grades of breast cancer lead us to investigate whether StarD13 
is indeed a tumor suppressor in our cells. Next, we wanted 
to investigate the role of StarD13 on cellular proliferation and 
viability. After confirming its GAP activity on RhoA and 
Cdc42 (Fig. 2A) by pull-down assay, we looked at the effect 
of StarD13 on proliferation. StarD13 was knocked down 
using small interfering siRNA in MDA-MB-231 cells. The 
resulting inhibition in the level of StarD13 was determined 
using western blotting and RT-PCR in cells transfected with 
2 different StarD13 siRNA oligos as compared to control cells 
transfected with non-specific siRNA where β-actin was used 
as a loading control (Fig. 2B). A 60% knockdown has been 
observed in western blotting (Fig. 2B). StarD13 knockdown 
resulted in a 40% decrease of dead cells as determined by 
trypan blue exclusion method (Fig. 2C).
On the other hand, as a second approach, cells were 
transfected with a GFP-StarD13 construct and the resulting 
cell viability was determined as compared to cells transfected 
with GFP vector alone. Cells overexpressing StarD13 showed a 
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drastic increase in the percentage of dead cells as compared to 
control cells as determined using trypan blue (Fig. 2C).
Moreover, this was reflected as an increase in cell viability 
in cells transfected with StarD13 siRNA by 18% as opposed to 
control cells as determined using Wst-1 reagent. In contrary, 
there was a dramatic decrease in cell viability in cells overex-
pressing StarD13 (Fig. 2D).
StarD13 effect on the cell cycle. Analysis of the cell cycle 
where cells were stained with propidium iodide alone showed 
that upon StarD13 knockdown, cells seem to undergo more 
cell division. This is apparent in the increase in the percentage 
of cells in the G2/M phase (38%) as opposed to control cells 
(28%) (Fig. 3).
StarD13 is needed for breast cancer cell motility. We were 
then interested in investigating the role of StarD13 in breast 
cancer cell motility. For this reason, StarD13 was knocked 
down using siRNA oligonucleotides (Fig. 2A). Results show 
that StarD13 knockdown significantly decreased the average 
speed of individual cells from 0.41 to 0.20 µm/min as deter-
mined by time-lapse motility movies (Fig. 4B). Looking at the 
morphology, both cell lines MCF-7 and MDA-MB-231 were 
observed to be stuck and not able to detach their tail in order 
to move forward (Fig. 4C). Moreover, StarD13 knockdown 
decreased the rate of wound closure from 14 µm/h to ~7 µm/h 
in both oligos tested (Fig. 4D and E). Also, the area of the 
wounds were calculated at 16 h following the formation of the 
wounds. The results show that in control cells only 47% of the 
initial wound area is left as opposed to StarD13 knockdown 
cells where the wounds areas did not appear to change after 
16 h, 80% for oligo1 and 77.16% for oligo2 (Fig. 4F). These 
results indicate that the knockdown of StarD13 inhibits breast 
cancer cell motility.
Regulation of RhoA and Rac activations is necessary for cell 
movement. After showing that RhoA knockdown inhibits 
cell motility (data not shown) and that StarD13 knockdown, 
Figure 1. StarD13 expression levels in different grades of breast cancer. (A) Representative fluorescent micrographs of formalin-fixed breast cancer tissues 
were paraffin-embedded and sectioned and then immunostained with anti-StarD113 antibody: in situ (upper left), grade I (upper right), grade II (lower left) 
and grade III (lower right). Quantitation of the immunohistochemistry in (A). The mean fluorescent intensity/pixel was measured and expressed to the cor-
responding tissues. (B) Data are the mean ± SEM from 3 different experiments (with 5 tissues each). *p<0.0001, **p<0.04. (C) Data analyzed from Oncomine 
website. mRNA of 60 samples were quantified for expression levels.
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where RhoA is kept active, also inhibits cell motility (Fig. 4) 
it was of great interest to us to determine the effect of overex-
pressing a constitutively active form of RhoA. Thus, similar 
to StarD13 knockdown, dominant active RhoA suppressed 
cellular motility. This was observed through wound healing 
assay where the rate of wound closure was decreased from 
12.3 to 3.4 µm/h (Fig. 5A). Knowing that Rac1 plays a major 
role in breast cancer motility and adhesion formation and 
knowing the antagonistic effect of Rho and Rac (20), we also 
opted to investigate the role of Rac1 in breast cancer cell 
motility. For this purpose, Rac1 was knocked down using a 
specific siRNA. The resulting expression level was detected 
by western blotting in cells transfected with Rac1 siRNA as 
compared to control cells transfected with non-specific siRNA 
(Fig. 5B). Results showed a decrease in the rate of wound 
closure in cells transfected with Rac1 siRNA to 9.4 µm/h as 
Figure 2. StarD13 on cell viability and proliferation. (A) MDA-MB-231 cells were transfected with either GFP alone (right lanes) or with GFP-StarD13 (left 
lanes). The cells were then lyzed and incubated with GST-RBD (Rhotekin binding domain) (upper pannels), or with GST-CRIB (Cdc42 and Rac interactive 
binding domain) (lower panels) to pull down active Rho and Cdc42, respectively. The samples were then blotted with Rho, and Cdc42 antibodies. The lower 
gels in each panel are western blots for the total cell lysates for loading control. The bands from the active RhoA gel were quantitated using ImageJ and 
normalized to the amount of total proteins. Data are the mean ± SEM of 3 blots from 3 independent experiments. (B) MDA-MB-231 cells were transfected 
with luciferase control siRNA or with StarD13 siRNA for 72 h. Two different siRNA oligos against StarD13 were used in each experiment. The cells were 
lysed and immunoblotted by western blot analysis for StarD13 (left upper gel) or for actin (left lower gel) for loading control. Quantitation represents 3 different 
blots from independent experiments. RT-PCR was also performed to detect StarD13 level using StarD13 primer (right upper gel) and actin as loading control 
(right lower gel). (C) Percentage (%) of dead cells was determined using trypan blue, results are shown as percent of total number of cells (left panel). Cells 
were transfected with GFP-StarD13 or GFP alone as control for 24 h. The percentage of dead cells showed an increase of 50% as determined using trypan 
blue (middle panel). Right panel is a quantitation from 3 different blots of cells transfected with either GFP or GFP-Stard13 and blotted for Star. (D) Cell 
proliferation was determined using WST-1 reagent. Cell viability of siRNA-transfected cells was expressed as fold increase from control (right panel). Cell 
proliferation dramatically decreased in cells transfected cells with GFP-StarD13 construct as opposed to control cells (right panel). Data are the mean ± SEM 
from 3 different experiments. *p<0.02, ***p<0.001, ****p<0.0001.
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compared to control cells (15.7 µm/h) (Fig. 5C). Since StarD13 
knockdown results in continuous activation of RhoA, we next 
looked at the effect StarD13 and RhoA double knockdown. 
In this case, the rate of wound closure observed was 6 µm/h 
(Fig. 5D and E) and almost 80% of the wound area remained 
after 16 h of wound formation (Fig. 5F). We also looked at 
the effect of StarD13 knockdown coupled with the expression 
of constitutively activated Rac1. This resulted in a 12.39 µm/h 
rate of wound closure as compared to 15.05 µm/h in control 
cells, thus indicating a rescuing effect.
StarD13 exerts its effects on RhoA and Rac in focal adhesions. 
Looking at the effect of StarD13 knockdown on the adhesion 
of breast cancer cells to collagen, our results show that cells 
with StarD13 knockdown have increased adhesion to collagen 
by >2-fold as compared to control cells (Fig. 6A).
After showing the effect of StarD13 on cell motility, we 
were interested in looking directly at focal adhesion under 
conditions where cells are deficient in Rac1 levels as well 
RhoA and StarD13. For this reason, we immunostained for 
Paxillin, a component of both focal complexes and focal adhe-
sions (17) using anti-paxillin antibody.
In cells with Rac1 knockdown, neither focal complexes nor 
focal adhesions were visible at the cell edge (Fig. 6B), which 
is correlated with reduced migration (Fig. 5C). This is in 
accordance with previous studies that have shown that Rac1 is 
needed for the initial formation of focal contacts (22). In cells 
with RhoA knockdown, focal adhesions were less prevalent 
compared to control cells; instead small punctate structures 
were highly present representing immature focal complexes 
(Fig. 6C). This was reflected in a 67% reduction in the average 
adhesion size as compared to control cells in the case of Rac1-
knockdown and 55% reduction in cells with RhoA knockdown 
(Fig. 6C). In cells with StarD13-KD; however, focal adhesions 
were more prominent and more pronounced especially at the 
cell edges as compared to control cells (Fig. 6B). Quantitatively, 
the average adhesion increased by ~34% compared to control 
cells (Fig. 6C). Consistent with our StarD13 siRNA knock-
down, we found that transfecting the cells with a dominant 
active form of RhoA lead to the stabilization of focal adhe-
sions (Fig. 6B). This was also reflected by a 13.5% increase 
in average adhesion size in cells transfected with a dominant 
active form of RhoA as compared to control cells (Fig. 6C).
StarD13 increases cellular invasion. After establishing the 
role of StarD13 in 2D cell migration, we were interested in 
determining its role in 3D cell invasion. For this reason, we 
performed an in vitro collagen-based invasion assay using 
FBS as a chemo-attractant. A chamber with serum-free media 
in both wells was used as negative control. To our surprise, 
unlike its effect in 2D, there was nearly a half-fold increase in 
cell invasion in cells with StarD13 knockdown as compared to 
control cells (Fig. 7).
Proposed model for StarD13 regulation. Our results showed 
that StarD13 negatively affects cellular proliferation. However, 
having a RhoGAP activity and localizing to focal adhesions 
of the cell, we showed that StarD13 actually plays an essential 
role in cellular motility. This correlated to the increase in its 
expression in metastatic forms of the tumor. In this context, 
Figure 3. StarD13 effect on the cell cycle. (A) MDA-MB-231 cells transfected with either control luciferase or StarD13 siRNA for 72 h. Cells were fixed 
overnight and stained with 10 µl of propidium iodide (PI). Cells were analyzed using a C6 flow cytometer, which indicated the distribution of the cells into 
their respective cell cycle phases based on their DNA content. G0/G1 cells were 2n, S-phase cells were >2n but <4n while G2/M cells were 4n. (B) Quantitation 
of (A). Data are the mean ± SEM from 3 different experiments.
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looking at the dynamics of focal adhesion, StarD13 seemed to 
be involved in the inhibition of RhoA following the maturation 
of FAs that results in the detachment and forward movement 
of the cell. Upon silencing StarD13 using siRNA, cells showed 
elongated tail morphology with stabilized focal adhesions and 
inhibitory cellular motility. However, this was not correlated 
in 3D mode, where we saw that cells with StarD13 knockdown 
seemed to have an enhanced invasive ability.
Discussion
In the present study, we opted to characterize StarD13 in breast 
cancer in terms of expression, effect on cell proliferation and 
viability, GAP activity and role in motility and invasion. 
Previous studies by Ching et al (12) identified StarD13 as a 
tumor suppressor gene in hepatocellular carcinoma cells. In 
the present study, we examined the role of StarD13 in breast 
Figure 4. StarD13 is needed for breast cancer cell motility. Cells were transfected with luciferase control siRNA or with StarD13 siRNA for 72 h. (A) The 
net paths of projected 120 frames from 2 h long time lapse movies of cells undergoing random motility in serum (upper right panel) (B) Quantitation of 
the cell speed from expressed in µm/min. Data are the mean ± SEM from n=20 cells. The results were significant with **p<0.001. (C) Montage of time-
lapse movie (60 sec apart) showing StarD13 siRNA-transfected cells undergoing random motility in serum (MCF-7, upper panel; and MDAs, lower panel). 
(D) MDA-MB-231 cells were grown in a monolayer then wounded and left to recover the wound then imaged at the same frame after 16 h (lower micrographs). 
(E) Quantitation of wound widths were measured at 11 different points for each wound, and the average rate of wound closure for the luciferase and the StarD13 
siRNA-transfected cells was calculated in µm/h (lower right panel). Data are the mean ± SEM from 3 wound closure assays from 3 independent experiments. 
The results were significant with **p<0.02, ***p<0.001. (F) The percentage of wound area at 16 h following wounding. Data are the mean ± SEM from 3 wound 
closure assays from 3 independent experiments. The results were significant with **p<0.002.
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Figure 5. Constitutive activation of RhoA inhibits cell motility. (A) MDA-MB-231 cells were left untransfected or transfected with a dominant active RhoA 
construct (RhoA DA). Cells were grown in a monolayer then wounded and left to recover the wound then imaged at the same frame after 16 h (lower micro-
graphs). Wound widths were measured at 11 different points for each wound, and the average rate of wound closure was calculated in µm/hr. Data are the 
mean ± SEM from 3 wound healing assays from 3 independent experiments. The results were significant with ***p<0.001. Right panel, cells were transfected 
as described, lysed and immunoblotted for RhoA. The gels were quantitated and data are the mean ± SEM from 3 different gels. (B) Western blot showing the 
decrease in Rac1 expression compared to actin (lower panel) in cells transfected with Rac1 siRNA compared to luciferase control (left lane). MDA-MB-231 
cells were grown in a monolayer then wounded and left to recover the wound then imaged at the same frame after 16 h (lower micrographs). Quantitation of 
wound widths were measured at 11 different points for each wound. (C) The average rate of wound closure for the luciferase and the Rac1 siRNA-transfected 
cells was calculated in µm/hr. Data are the mean ± SEM from 3 wound closure assays from 3 independent experiments. The results were significant with 
**p<0.01. (D) MDA-MB-231 cells were transfected with both StarD13-siRNA and RhoA-siRNA double knockdown or both StarD13-siRNA and Rac1-DA 
construct. Cells were grown in a monolayer then wounded and left to recover the wound then imaged at the same frame after 16 h. (E) The average rate of 
wound closure for the control and transfected cells was calculated in µm/hr. Data are the mean ± SEM from 3 wound closure assays from 3 independent 
experiments. The results were significant for the StarD13+RhoA-KD with **p<0.002 and not significant (ns) for StarD13KD+RacDA. (F) The percentage of 
wound area at 16 h following wounding. Data are the mean ± SEM from 3 wound closure assays from 3 independent experiments. The results were significant 
for the StarD13+RhoA-KD with **p<0.002 and not significant (ns) for StarD13KD+RacDA.
HANNA et al:  ROLE OF StarD13 IN BREAST CANCER1508
Figure 6. StarD13 exerts its effects on RhoA and Rac in focal adhesions. (A) Representative micrographs of cells fixed and stained with crystal violet to 
detect adhesion (as described in Materials and methods). Crystal violet was solubilized and the absorption of the plates was read at 550 µm using an ELISA 
plate reader. Data were measured in arbitrary units and normalized to the luciferase control. Data are the mean ± SEM from 3 experiments. The results were 
significant with p<0.001. (B) Representative micrographs of (MCF-7) cells that were transfected with either luciferase, Rac siRNA RhoA siRNA, StarD13 
siRNA and fixed and immunostained with anti-paxillin antibody. Cells that were transfected with RhoA-DA construct fixed and immunostained with anti-
paxillin antibody. Cells were imaged using a 60X objective. (C) Quantitation represented as average adhesion size in control cells and in cells with Rac, RhoA 
and StarD13 knockdown and in cells expressing RhoDA. Data are the mean ± SEM from n=15 cells. The results were significant with ***p<0.0001, *p<0.05. 
Scale bar represents 10 µm.
Figure 7. StarD13 knockdown increases cellular invasion. (A) Representative micrographs of invaded cells on the bottom side of the collagen-coated mem-
brane stained with cell stain according to assay instructions. MDA-MB-231 cells with StarD13 knockdown and control cells were allowed to invade towards 
10% FBS for 24 h. Cells/ml (1x106) were used in each assay. (B) Cell stain was extracted and colorimetric measurements were taken at 560 µm. Data are 
measured in arbitrary units.
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cancer cell proliferation and motility. Looking at its level 
of expression by IHC we revealed that StarD13 is highly 
expressed in non-tumor in situ form of breast cancer and it 
is downregulated in grades I and II, suggesting the potential 
role of StarD13 as a tumor suppressor in breast cancer. This 
was in accordance with previous studies where StarD13 was 
found to be underexpressed in several cancer types including 
lung, colon, gastric, ovarian, uterine, renal and rectal tumors 
(13). However, StarD13 showed a relatively high expression 
in highly metastatic forms of breast cancer. This was supple-
mented by data obtained from Oncomine database in which 
mRNA levels of StarD13 were reduced in grades I and II as 
compared to normal, however, were shown to increase in 
higher grades of the tumor. This was in accordance with a 
previous study in astrocytoma where StarD13 was shown to 
be overexpressed in grades III and IV as compared to grades I 
and II of the tumor (16).
We also showed that StarD13 has an anti-proliferative effect 
on breast cancer cells. This was evident when the overexpres-
sion of StarD13 dramatically increased cell death. In contrast, 
silencing StarD13 using specific siRNAs led to a decrease 
in cell death and an increase in cellular viability. Although 
no effect was apparent on apoptosis upon knocking down 
StarD13 these cells, further analysis of the cell cycle showed 
that silencing StarD13 lead to slight increase in dividing cells. 
This is consistent with its role as a tumor suppressor. Therefore, 
consistent with the literature, StarD13 seems to function as a 
tumor suppressor in breast cancer.
While examining the role of StarD13 in cell motility, we 
found that the knockdown of StarD13 in breast cancer cell 
lines inhibited cell motility. This may explain the increase 
of StarD13 expression in grades III obtained in IHC. Hence 
although being a tumor suppressor, this protein is needed for 
motility. Indeed, looking at their morphology, StarD13 knock-
down cells were immobilized and unable to detach their tail 
in order to retract their cell body and move forward. This was 
also reflected by an increase in cellular attachment through the 
stabilization of focal adhesions.
RhoA has been extensively proven to be indispensable for 
the formation of focal adhesions and for cell motility in several 
systems (18,19). Our data show that knockdown of RhoA leads 
to inhibition of cellular motility. As a RhoA-GAP, StarD13 
knockdown is hypothesized to result in continuous activation 
of RhoA. This surprisingly also led to an inhibition of cell 
motility. StarD13 and RhoA double knockdown also resulted 
in a dramatic inhibition of the cells ability to migrate. These 
experiments show that, while required for motility, consis-
tent RhoA activation inhibits it suggesting that RhoA needs 
to go through cycles of activation and inactivation. On the 
other hand, cells with StarD13 knockdown coupled with the 
expression of constitutively activated Rac1 showed increased 
migration ability in wound healing similar to StarD13 
knockdown cells indicating a rescuing effect. This could be 
explained by the antagonistic relationship between RhoA and 
Rac. When StarD13 is knocked down, RhoA is constitutively 
active which inhibits Rac. This inhibits motility as Rac is 
also required for motility. Furthermore, it has been previously 
shown that increasing Rho activation inhibits the dissolution 
of focal adhesions at the tail of moving cells, inhibiting cell 
motility (20,21). Thus, we formulated the hypothesis that 
StarD13 knockdown is keeping RhoA active in focal adhe-
sions at the tail leading to the inhibition of cell motility. This 
persistent activation of RhoA is also keeping Rac inhibited not 
allowing Rac to initiate focal complexes which are precursors 
for focal adhesions as described below.
Knowing that Rac1 plays a major role in breast cancer 
motility and adhesion formation and knowing the antago-
nistic effect of RhoA and Rac (20), we started by looking at 
the dynamics of cellular adhesion directly following Rac and 
RhoA knockdowns. In cells with Rac knockdown, neither 
focal complexes nor focal adhesions were observed. This is 
in accordance with the fact that Rac is needed for the forma-
tion of focal complexes (22). Moreover, cells underexpressing 
RhoA showed inability to form mature focal adhesions. 
Similarly previous studies done on MTLn3 cells showed that 
inhibition of RhoA downstream effector ROCK blocked the 
maturation of focal adhesions in MTLn3 cells (23). However, 
silencing StarD13 led to the stabilization of focal adhesions 
and decrease in focal complexes. Hence, we suspected that 
cells with StarD13 knockdown, seem to have a constitutively 
active RhoA stabilizing cellular adhesion to the underlying 
substratum and impeding tail retraction resulting in inhibition 
of cell motility. The disassembly of focal adhesions is required 
for the completion of the cell motility cycle. This suggests that 
StarD13 plays a role in inhibiting RhoA leading to the detach-
ment of the cell. In this sense, overexpressing a dominant active 
form of RhoA would mimic StarD13 knockdown phenotype in 
cell motility and adhesion. Indeed, transfecting the cells with 
a constitutively active RhoA inhibited cell motility and cells 
showed larger and more abundant focal adhesions relative to 
focal complexes. Similar studies involving the use of domi-
nant active RhoA have demonstrated an inhibition of cellular 
motility (24-26).
Taken together, our data show that even though StarD13 
is known to be a tumor suppressor, it is needed for motility. 
This controverts traditional concepts regarding definite roles 
of tumor suppressors versus oncogenes in different cancer 
types. Studies done on DLC1, a closely related gene, reported 
its function as a candidate tumor suppressor in hepatocellular 
carcinoma (27). Further studies showed that hypermethyl-
ation of DLC1 gene promoter is responsible for the loss of its 
function as a tumor suppressor in a subset of liver, colon and 
prostate cancers (15,28-30). Other studies also confirm the 
role of DLC1 as a tumor suppressor (29). In this framework, 
overexpression of DLC1 was shown to exhibit inhibitory 
effects on cell growth and proliferation in hepatocellular 
and breast cancer (28,30,31). Moreover, DLC1 activity was 
shown to positively regulate the cytoskeleton and ultimately 
cell motility. This regulatory mechanism was linked to the its 
negative regulation of RhoA through its GAP activity (32,33). 
Another recent study done on normal prostate cells showed 
that silencing of DLC1 reduces migration (34). In fact, recent 
studies showed that DLC1 plays differential roles in regulating 
cell migration and transformation depending on its interaction 
with tensins (35). This highlights the differential role of the 
DLC family of proteins as tumor suppressors yet needed for 
cell motility. A comparable dilemma is illustrated in a recent 
review on TGF-β that is known to exert tumor-suppressive 
effects in normal cells yet paradoxically, in protumorigenic 
cells its role is reversed (36).
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After determining the mechanism by which StarD13 might 
affect random 2D cell motility, it was intriguing to study its 
effect on cellular invasion in 3D. For this we transfected the 
cells with siRNA against starD13 and performed collagen-based 
transwell invasion assay. Knowing that StarD13 knockdown 
inhibited cellular motility in 2D it was assumed that it would 
also inhibit cell invasion. However, to our ultimate surprise, 
silencing StarD13 had a positive effect on cellular invasion, 
despite the fact that StarD13 knockdown stabilizes focal 
adhesions. This might be due to focal adhesions playing an 
unconventional role in cellular invasion. A recent report exists 
on the contribution of focal adhesions to matrix degradation. 
Results revealed that several cell lines degraded underlying 
ECM specifically at focal adhesion sites. This process occurred 
through proteolytic activity of MMPs and not due to physical 
tension exerted by FAs onto the matrix (37). Moreover, other 
studies demonstrated that silencing RhoA leads to the inhibi-
tion of cellular invasion, particularly in breast cancer cell lines 
(38,39). This solidifies our data with starD13 knockdown where 
we typically have an increase in RhoA activity, thus promoting 
cellular invasion. Moreover, it was previously discovered that 
in 3D matrices, tumor cells are able to switch between distinct 
modes of motility (40). This pertains to the interplay between 
different signaling requirements. Thus, cells can switch 
between a rounded blebbing movement and a more elongated 
protrusive fashion. Thus in our study, the depletion of StarD13 
increased cellular adhesion to the ECM impeding 2D mesen-
chymal cellular migration; however, this was reflected in an 
increase in 3D movement. This suggests that when cells cannot 
move in an adhesion-dependent manner, they tend to switch to 
a more amoeboid fashion. Therefore, the ability of tumor cells 
to switch between modes of motility may limit the effective-
ness of prospective inhibitory strategies targeting particular 
cell morphology, hence promoting the selection of a different 
mode to escape inhibition.
We conclude that StarD13 tumor suppressor activity is 
contextual where tumor cells manage to exploit alternative 
mechanisms to escape inhibition. This reveals the impor-
tance of understanding the complexity and diversity of these 
pathways as a tool in paving the way for finding potential 
therapeutic targets.
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